Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Br J Pharmacol
2004 May 01;1421:172-80. doi: 10.1038/sj.bjp.0705738.
Show Gene links
Show Anatomy links
R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter.
Stórustovu Sí
,
Sánchez C
,
Pörzgen P
,
Brennum LT
,
Larsen AK
,
Pulis M
,
Ebert B
.
???displayArticle.abstract???
1. Clinical observations with the selective serotonin reuptake inhibitor (SSRI), S-citalopram, indicate that S-citalopram is more efficacious and produces earlier symptom relief than RS-citalopram. Since R-citalopram is at least 20-fold weaker than S-citalopram as inhibitor of the 5-HT transporter (SERT) in preclinical studies, the clinical data suggest an unexpected antagonistic interaction between the two enantiomers. We therefore characterised the interaction of R- and S-citalopram with the SERT in in vivo and in vitro assays. 2. In both behavioural (potentiation of 5-hydroxytryptophan (5-HTP)-induced behaviour) and electrophysiological studies (inhibition of 5-HT-elicited ion currents in Xenopus oocytes expressing the human SERT (hSERT) R-citalopram inhibited the effects of S-citalopram in a dose-dependent manner. With S-citalopram : R-citalopram ratios of 1 : 2 and 1 : 4, 5-HTP potentiation was significantly smaller than with S-citalopram alone. 3. R-citalopram did not antagonise the effects of another SSRI (fluoxetine) in either behavioural or electrophysiological studies. 4. In oocytes, inhibition of hSERT-mediated currents by R-citalopram was almost completely reversible and characterised by fast on- and off-sets of action. In contrast, the off-set for S-citalopram was 35-fold slower than for R-citalopram. 5. Kinetic analysis of the oocyte experiments suggests that S-citalopram binding to SERT induces a long-lasting, inhibited state of the transporter and that coapplication of R-citalopram partially relieves SERT of this persistent inhibition. 6. We propose that the kinetic interaction of R- and S-citalopram with SERT is a critical factor contributing to the antagonistic effects of R-citalopram on S-citalopram in vitro and in vivo.
Amara,
Neurotransmitter transporters: recent progress.
1993,
Pubmed
Andersen,
[3H]GBR 12935 binding in vivo in mouse brain: labelling of a piperazine acceptor site.
1987,
Pubmed
Artigas,
Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors.
1994,
Pubmed
Artigas,
Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists.
1996,
Pubmed
Blier,
Current advances and trends in the treatment of depression.
1994,
Pubmed
Blier,
Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response.
1997,
Pubmed
Bräuner-Osborne,
Functional partial agonism at cloned human muscarinic acetylcholine receptors.
1996,
Pubmed
Chalon,
Pharmacological characterization of N,N-dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a ligand of the serotonin transporter with high affinity and selectivity.
2003,
Pubmed
Ebert,
Molecular pharmacology of the AMPA agonist, (S)-2-amino-3-(3-hydroxy-5-phenyl-4-isoxazolyl)propionic acid [(S)-APPA] and the AMPA antagonist, (R)-APPA.
1994,
Pubmed
Hyttel,
The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer.
1992,
Pubmed
Kugelberg,
In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats.
2001,
Pubmed
Larsen,
Selectivity of (3)H-MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects.
2004,
Pubmed
Lepola,
Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.
2003,
Pubmed
Liman,
Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs.
1992,
Pubmed
,
Xenbase
Mager,
Conducting states of a mammalian serotonin transporter.
1994,
Pubmed
,
Xenbase
Montgomery,
Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model.
2001,
Pubmed
Mortensen,
Molecular cloning, expression and characterization of a bovine serotonin transporter.
1999,
Pubmed
Mørk,
The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats.
2003,
Pubmed
Quick,
Substrates regulate gamma-aminobutyric acid transporters in a syntaxin 1A-dependent manner.
2002,
Pubmed
Ramamoorthy,
Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants.
1999,
Pubmed
Smith,
Measurement of protein using bicinchoninic acid.
1985,
Pubmed
Sonders,
Channels in transporters.
1996,
Pubmed
Sánchez,
R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model.
2003,
Pubmed
Sánchez,
Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.
2003,
Pubmed
Whitworth,
Psychostimulants differentially regulate serotonin transporter expression in thalamocortical neurons.
2002,
Pubmed
